The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
Abstract
Purpose: To assess the safety, efficacy, and immunomodulatory effects of CC-4047 (Actimid; Celgene, San Diego, CA) in patients with relapsed or refractory myeloma. Patients and Methods: Twenty-four relapsed or refractory patients were treated with a dose-escalating regimen of oral CC-4047. Clinical responses and adverse effects were identified, and peripheral T-cell subsets, serum cytokines, and proangiogenic factors were evaluated. Results: CC-4047 was tolerated with no serious nonhematologic adverse events. All patients were eligible for analysis. Toxicity criteria during the initial 4 weeks of study were used to define the maximum-tolerated dose (MTD). During this period, one patient withdrew with a deep vein thrombosis (DVT) probably caused by an undiagnosed primary melanoma with lymphadenopathy in the groin, one patient withdrew because of progressive disease (PD), and three patients discontinued with neutropenia. Nineteen of 24 patients continued on treatment beyond 4 weeks to PD or development of a serious adverse event. Three further patients developed a DVT at 4, 9, and 11 months. Treatment resulted in a greater than 25% reduction in paraprotein in 67% of patients, 13 patients (54%) experienced a greater than 50% reduction in paraprotein, and four (17%) of 24 patients entered complete remission. The MTD was 2 mg/d. All patients showed increased CD45RO expression on CD4+and CD8+cells, with a concomitant decrease in CD45RA+cells. CC-4047 treatment was associated with significantly increased serum interleukin (IL)-2 receptor and IL-12 levels, which is consistent with activation of T cells and monocytes and macrophages. Conclusion: This study demonstrates the safety and efficacy of CC-4047. The MTD of CC-4047 orally was 2 mg/d. This is the first report demonstrating in vivo T-cell costimulation by this class of compound, supporting a potential role for CC-4047 as an immunostimulatory adjuvant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Thalidomide is an inhibitor of angiogenesis.
D'Amato, R. J., Loughnan, M. S., Flynn, E., & Folkman, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.4082 · Cited by 2,454
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., & Gately, M. K. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.4.1223 · Cited by 1,197
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Richardson, P. G., Schlossman, R. L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L. P., Doss, D., Kelly, K., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0996 · Cited by 804
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L. M., Ocampo, C. J., Patterson, R. T., Stirling, D., & Kaplan, G. (1999) · PubMed · Cited by 729
Corral, L. G., Haslett, P. A. J., Muller, G. W., Chen, R., Wong, L.-M., Ocampo, C. J., Patterson, R. T., Stirling, D. I., & Kaplan, G. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.380 · Cited by 656
Haslett, P. A. J., Corral, L. G., Albert, M., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 573
Coughlin, C. M., Salhany, K. E., Wysocka, M., Aruga, E., Kurzawa, H., Chang, A. E., Hunter, C. A., Fox, J. C., Trinchieri, G., & Lee, W. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1555 · Cited by 415
Hideshima, T., Chauhan, D., Schlossman, R., Richardson, P., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204623 · Cited by 394
Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H.-W., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600607 · Cited by 296
Self-citationGeitz, H., Handt, S., & Zwingenberger, K. (1996) · Immunopharmacology · doi:10.1016/0162-3109(95)00050-x · Cited by 291
Mchugh, S. M., Rifkin, I. R., Deighton, J., Wilson, A. B., Lachmann, P. J., Lockwood, C. M., & Ewan, P. W. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb05527.x · Cited by 263
Österborg, A., Yi, Q., Henriksson, L., Fagerberg, J., Bergenbrant, S., Jeddi-Tehrani, M., Rudén, U., Lefvert, A.-K., Holm, G., & Mellstedt, H. (1998) · Blood · doi:10.1182/blood.v91.7.2459 · Cited by 189
Dredge, K., Marriott, J. B., Todryk, S. M., Muller, G. W., Chen, R., Stirling, D. I., & Dalgleish, A. G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4914 · Cited by 162
Self-citationMarriott, J. B., Clarke, I., Dredge, K. S., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01954.x · Cited by 155
Self-citationThalidomide and Deep Vein Thrombosis in Multiple Myeloma: Risk Factors and Effect on Survival
Zangari, M., Barlogie, B., Thertulien, R., Jacobson, J. L., Eddleman, P., Fink, L. M., Fassas, A., van Rhee, F., Talamo, G., Lee, C.-K., et al. (2003) · Clinical Lymphoma · doi:10.3816/clm.2003.n.011 · Cited by 112
Giuliani, N., Colla, S., Lazzaretti, M., Sala, R., Roti, G., Mancini, C., Bonomini, S., Lunghi, P., Hojden, M., Genestreti, G., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3257 · Cited by 112
Thalidomide in the management of multiple myeloma
Barlogie, B., Zangari, M., Spencer, T., Fassas, A., Anaissie, E. J., Badros, A., Cromer, J., & Tricot, G. J. K. (2001) · Seminars in Hematology · doi:10.1016/s0037-1963(01)90017-4 · Cited by 103
Nakajima, A., Kodama, T., Morimoto, S., Azuma, M., Takeda, K., Oshima, H., Yoshino, S., Yagita∥, H., & Okumura, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.4.1901 · Cited by 90
Deregulated cytokine network and defective Th1 immune response in multiple myeloma
Frassanito, M. A., Cusmai, A., & Dammacco, F. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01582.x · Cited by 85
Neben, K., Moehler, T. M., Kraemer, A., Benner, A., Egerer, G., Ho, A. D., & Goldschmidt, H. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03142.x · Cited by 69
Thromboembolic events during treatment with thalidomide
Urbauer, E., Kaufmann, H., Nösslinger, T., Raderer, M., & Drach, J. W. (2002) · Blood · doi:10.1182/blood-2001-12-0245 · Cited by 68
Thalidomide and immunomodulatory drugs as cancer therapy
Raje, N. S., & Anderson, K. C. (2002) · Current Opinion in Oncology · doi:10.1097/00001622-200211000-00008 · Cited by 68
Schey, S., Cavenagh, J. D., Johnson, R. J., Child, J. A., Oakervee, H. E., & Jones, R. W. (2003) · Leukemia Research · doi:10.1016/s0145-2126(03)00027-4 · Cited by 66
Self-citationImmunotherapeutic and antitumour potential of thalidomide analogues
Marriott, J. B., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.4.675 · Cited by 52
Self-citationThalidomide analogs as emerging anti-cancer drugs
Dredge, K. S., Dalgleish, A. G., & Marriott, J. B. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200306000-00001 · Cited by 42
Self-citationThalidomide in the Management of Multiple Myeloma
Schey, S. (2002) · Hematology · doi:10.1080/1024533021000037199 · Cited by 3
Self-citationSchey, S. (2003) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(03)00006-5 · Cited by 1
Self-citation
Cited by
Miguel, J. S., Weisel, K., Moreau, P., Lacy, M., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 801
Self-citationTargeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
Galustian, C., Meyer, B., Labarthe, M.-C., Dredge, K., Klaschka, D., Henry, J., Todryk, S., Chen, R., Muller, G., Stirling, D., et al. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0620-4 · Cited by 391
Self-citationRichardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538835 · Cited by 381
Chemotherapy-induced thrombosis
Haddad, T. C., & Greeno, E. W. (2006) · Thrombosis Research · doi:10.1016/j.thromres.2005.10.015 · Cited by 359
Metadata
- Authors
- Schey, S. A., Fields, P., Bartlett, J. B., Clarke, I. A., Ashan, G., Knight, R. D., Streetly, M., & Dalgleish, A. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-08-15
- Volume
- 22
- Issue
- 16
- Pages
- 3269-3276
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1975916512
- Cited by
- 314
- References
- 32
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.